Eisai EMEA dans l'actualité
Développement de médicaments innovants axés sur le patient
Tamtam a trouvé 20 articles récents sur Eisai EMEA.
- Eisai wins EMA acceptance for lemborexant insomnia filing in Europe
- LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026
- Slovenia's Salus signs lecanemab distribution deal with Eisai EMEA
- Eisai claims UK grant to expand manufacturing site
- Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China
- Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
- Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
- Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025
- Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan
- Eisai shares long-term data on lecanemab at neurology congress
- Eisai, Biogen's Alzheimer's med Leqembi wins long-awaited European approval
- Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia
- The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer’s Disease
- 5 minutes with… Jaime Manzanera, Eisai
- Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
- Eisai, Biogen's Alzheimer's med Leqembi turned down in Europe—but analyst says it's merely a 'delay'
- FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
- Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease to the U.S. FDA
- Eisai: Laying the Foundation for Centralized Medical Information Management
- Japanese Pharmaceutical Company Eisai Expands UK Site with New Facility
Articles collectés par Tamtam et retenus lorsqu'ils portent sur l'entreprise, des plus récents aux plus anciens. Chacun renvoie à sa source.
Vous vendez à des entreprises comme Eisai EMEA ?
Tamtam trouve les entreprises qui correspondent à votre client idéal, analyse chaque compte et vous dit qui contacter, et quand.
Trouver des entreprises similaires